USPTO Grants Codexis Patent for Enzymes Used in Hepatitis-C Therapeutics

Codexis (Redwood City, CA) says that the United States Patent and Trademark Office (USPTO; Alexandria, VA) has granted Codexis’ patent covering the biocatalysts and biocatalytic processes used to make key pharmaceutical intermediates in the synthesis of hepatitis-C therapeutics. The term of this patent does not expire until 2029. The patent is titled “Biocatalytic processes for the preparation of substantially stereomerically pure fused bicyclic proline compounds” and was issued as U.S. patent number 8,178,333. “This patent specifically...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers